Diagnostic Approaches for Chronic Myeloid Leukaemia

Chronic myeloid leukaemia (CML) is a type of blood cancer that can be diagnosed through various diagnostic approaches. A patient with elevated total leukocyte and neutrophil counts, mild anaemia, and an elevated platelet count, along with numerous myeloid line cells in different stages of differentiation, is likely to have CML. However, to confirm the diagnosis, a genotype study is necessary to demonstrate the cytogenetic hallmark of t(9:22). This can be done through molecular methods like fluorescence in situ hybridisation or cytogenetic analysis.

A bone marrow study can also be performed, which will show a greatly increased myeloid: erythroid ratio, but it will not help in confirming the diagnosis. Similarly, a low leukocyte alkaline phosphatase (LAP) score can differentiate from a leukemoid reaction but cannot confirm the diagnosis. Immunophenotyping can show cells of myeloid lineage but cannot provide a definitive diagnosis.

Iron kinetics studies are not necessary in this case as the increased total leukocyte count and peripheral smear picture suggest a chronic myeloproliferative state rather than iron deficiency. In conclusion, a genotype study is the most appropriate next step to confirm the diagnosis of CML.

Understanding Von Willebrand’s Disease

Von Willebrand’s disease is a common inherited bleeding disorder that is usually passed down in an autosomal dominant manner. It behaves like a platelet disorder, with symptoms such as nosebleeds and heavy menstrual bleeding being common, while joint and muscle bleeding are rare. The disease is caused by a deficiency or abnormality in von Willebrand factor, a large glycoprotein that promotes platelet adhesion to damaged endothelium and acts as a carrier molecule for factor VIII.

There are three types of Von Willebrand’s disease. Type 1 is the most common and is characterized by a partial reduction in von Willebrand factor. Type 2 is further divided into four subtypes, each with a different abnormality in the von Willebrand factor. Type 3 is the most severe form and is caused by a total lack of von Willebrand factor, inherited in an autosomal recessive manner.

Diagnosis of Von Willebrand’s disease involves tests such as a prolonged bleeding time, APTT, factor VIII levels, and platelet aggregation with ristocetin. Management options include tranexamic acid for mild bleeding, desmopressin to raise levels of von Willebrand factor, and factor VIII concentrate. While there is no clear correlation between symptomatic presentation and type of Von Willebrand’s disease, common themes among patients include excessive mucocutaneous bleeding, bruising in the absence of trauma, and menorrhagia in females.

Pulmonary fibrosis is a potential side effect of bleomycin, a cytotoxic antibiotic commonly prescribed for metastatic germ cell cancer, squamous cell carcinoma, and non-Hodgkin’s lymphoma. The severity of this adverse effect is directly proportional to the dosage administered.

Cytotoxic agents are drugs that are used to kill cancer cells. There are several types of cytotoxic agents, each with their own mechanism of action and adverse effects. Alkylating agents, such as cyclophosphamide, work by causing cross-linking in DNA. However, they can also cause haemorrhagic cystitis, myelosuppression, and transitional cell carcinoma. Cytotoxic antibiotics, like bleomycin, degrade preformed DNA and can lead to lung fibrosis. Anthracyclines, such as doxorubicin, stabilize the DNA-topoisomerase II complex and inhibit DNA and RNA synthesis, but can also cause cardiomyopathy. Antimetabolites, like methotrexate, inhibit dihydrofolate reductase and thymidylate synthesis, leading to myelosuppression, mucositis, liver fibrosis, and lung fibrosis. Fluorouracil (5-FU) is a pyrimidine analogue that induces cell cycle arrest and apoptosis by blocking thymidylate synthase, but can also cause myelosuppression, mucositis, and dermatitis. Cytarabine is a pyrimidine antagonist that interferes with DNA synthesis specifically at the S-phase of the cell cycle and inhibits DNA polymerase, but can also cause myelosuppression and ataxia. Drugs that act on microtubules, like vincristine and vinblastine, inhibit the formation of microtubules and can cause peripheral neuropathy, paralytic ileus, and myelosuppression. Docetaxel prevents microtubule depolymerisation and disassembly, decreasing free tubulin, but can also cause neutropaenia. Topoisomerase inhibitors, like irinotecan, inhibit topoisomerase I which prevents relaxation of supercoiled DNA, but can also cause myelosuppression. Other cytotoxic drugs, such as cisplatin, cause cross-linking in DNA and can lead to ototoxicity, peripheral neuropathy, and hypomagnesaemia. Hydroxyurea (hydroxycarbamide) inhibits ribonucleotide reductase, decreasing DNA synthesis, but can also cause myelosuppression.

A possible diagnosis for an older woman with a labial lump and inguinal lymphadenopathy is vulval carcinoma, especially if the lump is firm and has grown rapidly over a short period of time. Risk factors for this condition include advanced age, smoking, and HPV infection. Bartholin’s cyst, condylomata lata, lipoma, and sebaceous cyst are less likely diagnoses, as they do not typically present with the same symptoms or risk factors as vulval carcinoma.

Understanding Vulval Carcinoma

Vulval carcinoma is a type of cancer that affects the vulva, which is the external female genitalia. It is a relatively rare condition, with only around 1,200 cases diagnosed in the UK each year. The majority of cases occur in women over the age of 65 years, and around 80% of cases are squamous cell carcinomas.

There are several risk factors associated with vulval carcinoma, including human papilloma virus (HPV) infection, vulval intraepithelial neoplasia (VIN), immunosuppression, and lichen sclerosus. Symptoms of vulval carcinoma may include a lump or ulcer on the labia majora, inguinal lymphadenopathy, and itching or irritation.

It is important for women to be aware of the risk factors and symptoms of vulval carcinoma, and to seek medical attention if they experience any concerning symptoms. Early detection and treatment can improve outcomes and increase the chances of a full recovery.

Treatment Options for Chronic Lymphocytic Leukaemia (CLL)

The National Institute for Health and Care Excellence (NICE) has released new guidelines for managing newly diagnosed CLL in adults. Acalabrutinib is recommended as a monotherapy option if the patient has a 17p deletion or TP53 mutation, or if fludarabine plus cyclophosphamide and rituximab (FCR) or bendamustine plus rituximab (BR) are unsuitable. Prednisolone, a glucocorticoid commonly used in treating lymphoma, has no role in managing CLL. If there is no 17p deletion or TP53 mutation, FCR or BR would be the most appropriate first-line treatment. Conservative management is not recommended as the patient has developed signs of bone marrow dysfunction. Imatinib, the first-line treatment for CML, would not be useful for CLL.

Palliative Care Prescribing for Agitation and Confusion

When dealing with agitation and confusion in palliative care patients, it is important to identify and treat any underlying causes such as hypercalcaemia, infection, urinary retention, or medication. If these specific treatments fail, medication can be used to manage symptoms. Haloperidol is the first choice for treating agitation and confusion, with chlorpromazine and levomepromazine as alternative options. In the terminal phase of the illness, midazolam is the preferred medication for managing agitation or restlessness. Proper management of these symptoms can greatly improve the quality of life for palliative care patients.

Metastasis and Spread of Common Cancers

Gastric carcinoma, the fifth most common cancer worldwide, often presents with advanced disease and can affect various parts of the stomach. Troisier’s sign, an enlarged left supraclavicular node, is a telltale sign of gastric carcinoma, but cancers from other gastrointestinal and urogenital sites can also present with this symptom.

Endometrial cancer, or cancer of the corpus uteri, typically spreads to pelvic and para-aortic nodes, as well as distant organs like the lungs, liver, brain, and bones. Epigastric pain, hepatomegaly, jaundice, and ascites may indicate poor prognosis.

Lung cancers tend to spread to deep lymph nodes in the mediastinum and thorax, as well as the other lung, pleura, and distant organs.

Renal carcinoma first spreads to local lymph nodes before invading the aorta and vena cava. It can also spread to more distant lymph nodes, bones, liver, and lungs.

Prostate cancer can spread to local and regional lymph nodes, but it is also known to spread to the bones, causing severe pain, especially in the femur.

Tumour Markers for Common Cancers

Tumour markers are substances produced by cancer cells that can be detected in the blood. They are used to help diagnose and monitor the progression of cancer. Here are the most common tumour markers associated with some of the most prevalent cancers:

Hepatocellular carcinoma: Alpha-fetoprotein (AFP) is the most likely tumour marker associated with this type of liver cancer, which often develops in people with chronic liver diseases.

Breast cancer: Cancer antigen 15-3 (CA 15-3) is the most likely tumour marker associated with breast cancer, which affects both men and women.

Colorectal cancer: Carcinoembryonic antigen (CEA) is the most likely tumour marker associated with colorectal cancer, which can develop from polyps in the colon or rectum.

Pancreatic cancer: CA 19-9 is the most likely tumour marker associated with pancreatic cancer, which is often difficult to detect in its early stages.

Prostate cancer: Prostate-specific antigen (PSA) is the most likely tumour marker associated with prostate cancer, which is the most common cancer in men.

Differentiating Leukaemia and Lymphoma: Characteristics and Symptoms

Leukaemia and lymphoma are both types of blood cancer, but they have distinct characteristics and symptoms. In this context, we will discuss the characteristics and symptoms of chronic lymphocytic leukaemia (CLL), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML), Hodgkin’s lymphoma (HL), and multiple myeloma (MM).

CLL is the most common leukaemia in adults, characterized by peripheral blood lymphocytosis and uncontrolled proliferation of B cell lymphocytes in the bone marrow, lymph nodes, and splenomegaly. Patients are often asymptomatic, and CLL is often picked up incidentally.

ALL is a common leukaemia of children aged 2–5 years and is very rare in adults.

CML tends to present with more systemic, B symptoms in a slightly younger age group. A classic symptom is a massive hepatosplenomegaly. Blood film would show PMNs, basophils, and myelocytes.

HL is a possibility in this age group; however, the question asks for the ‘most likely’ diagnosis, which would be CLL as it is more common in this age group and the western world. Further investigation would be used to confirm the diagnosis.

MM is the uncontrolled proliferation of plasma cells and does not present in the way described above. Bone pain, hypercalcaemia, renal failure, and neutropenia are common presentations.

The primary treatment for polycythaemia vera is venesection, which is used to maintain normal levels of haemoglobin. This patient is displaying symptoms consistent with the condition, including pruritis, numbness and tingling in the extremities, headaches, lethargy, and splenomegaly. Venesection involves removing blood from the patient to reduce haemoglobin levels, and may need to be performed weekly initially, but can be spaced out to every 6-12 weeks once the condition is under control. Ibuprofen is not a recommended treatment for polycythaemia vera, but aspirin can be used to reduce the risk of clotting. Paroxetine has been studied as a treatment for pruritis associated with polycythaemia vera, but should not be used as a replacement for venesection. Ruxolitinib is a medication used to prevent thrombus formation in patients who are resistant or intolerant to hydroxyurea, but is not a first-line treatment for the condition.

Polycythaemia vera is a condition where a single marrow stem cell undergoes clonal proliferation, leading to an increase in red cell volume, as well as an overproduction of neutrophils and platelets. This disorder is most commonly seen in individuals in their sixth decade of life and is characterized by symptoms such as hyperviscosity, pruritus, and splenomegaly.

The management of polycythaemia vera involves several approaches. Aspirin is often prescribed to reduce the risk of thrombotic events. Venesection is the first-line treatment to keep the haemoglobin levels within the normal range. Chemotherapy, such as hydroxyurea, may also be used, but it carries a slight increased risk of secondary leukaemia. Phosphorus-32 therapy is another option.

The prognosis for polycythaemia vera is variable. Thrombotic events are a significant cause of morbidity and mortality. Additionally, 5-15% of patients may progress to myelofibrosis, while another 5-15% may develop acute leukaemia, with the risk being increased with chemotherapy treatment.